University of Tasmania
Browse

File(s) not publicly available

PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events - economic implications?

journal contribution
posted on 2023-05-17, 09:27 authored by Bottomley, J, Andrew Palmer, Williams, R, Dormandy, J, Massi-Benedetti, M
Economic value of medicines, medical devices and other technologies is an increasingly important consideration in healthcare management. Conducting high quality economic analyses alongside randomised controlled clinical trials (RCTs) is desirable since these offer timely information with high internal validity. The recent publication of the landmark PROactive study provides a relevant platform upon which to base a detailed economic evaluation of the possible additional benefit of pioglitazone over and above current best treatment in patients with type 2 diabetes with severe cardiovascular (CV) disease. Pioglitazone improved CV outcome and reduced the need to add insulin to existing therapy in individuals at high risk of further macrovascular events. The predefined economic analysis of this study using well-accepted methods will inform the cost effectiveness (CE) of pioglitazone confirming (or not) its value in the management of patients with type 2 diabetes with severe CV disease.

History

Publication title

British Journal of Diabetes and Vascular Disease

Volume

6

Pagination

63-70

ISSN

1474-6514

Department/School

Menzies Institute for Medical Research

Publisher

Sage Publications Ltd.

Place of publication

United Kingdom

Repository Status

  • Restricted

Socio-economic Objectives

Evaluation of health and support services not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC